The content on this site is intended for healthcare professionals only
Dr. Luis Raez speaks to ecancer on the data presented at the ASCO Direct Highlights 2022 on adjuvant and neoadjuvant immunotherapy in lung cancer.
Adjuvant immunotherapy was FDA approved last year, with this year being the first for new adjuvant chemoimmunotherapy.
At the previous ASCO, more information was found supporting the two approvals. The first being the new adjuvant immunotherapy.
One study, Checkmate A16 showed a series of three cycles of chemo with immunotherapy as a standard of care. There is a good complete response and response rate.
At this ASCO, there is a second study to support these findings. Results show a 6% to 30% describe in tumour growth.
The Vanessa Moss Prize: celebrating research into cancer health disparities
Prostate cancer
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
The Southeast Asian Breast Cancer Symposium; background, aims and successes
Choosing Wisely in radiology Tanzania
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
